Eli Lilly blows past estimates, hikes guidance as Zepbound and Mounjaro sales soar

Core Insights - Eli Lilly reported third-quarter earnings and revenue that exceeded analyst expectations, driven by strong demand for its weight loss drug Zepbound and diabetes treatment Mounjaro [1][3] - The company raised its full-year outlook, indicating confidence in continued growth in the GLP-1 drug market [1] Financial Performance - Adjusted earnings per share were $7.02, surpassing the expected $5.69 [3] - Revenue reached $17.60 billion, exceeding the anticipated $16.01 billion [3] Market Position - Eli Lilly is focused on maintaining its competitive edge over Novo Nordisk in the rapidly growing market for GLP-1 obesity and diabetes drugs [1]